Compare AbbVie Inc (ABBV) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

PBW trades at $37.52, up 2.57% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF lacks key valuation metrics like P/E and P/S, and recent news highlights its volatility tied to interest rates and clean energy sector momentum. A dividend of $0.24 is scheduled for June 2026, but financial statements for the current period are unavailable.

The outlook is cautious due to bearish technicals and sensitivity to Treasury yields, though clean energy tailwinds from energy security concerns offer potential. Risks include rate cycle volatility and sector competition, with investor sentiment mixed amid Nasdaq pressures.